Group 1 - Hubei Province's direct financing has maintained a high level of around 800 billion yuan for three consecutive years, with nearly 80% of listed companies achieving profitability [1][2] - As of June 30, 2025, Hubei has 191 listed companies, ranking 10th nationally, with 153 domestic and 38 overseas listings [2][3] - The province has a reserve of 1,355 "gold and silver seed" enterprises to support more quality companies to go public [1][4] Group 2 - In Q1 2025, over 70% of Hubei's listed companies were profitable, with notable companies like Jiuzhoutong, CITIC Special Steel, and Wentai Technology reporting revenues exceeding 10 billion yuan [3] - The top ten companies by revenue in Hubei all exceeded 4 billion yuan, indicating strong performance in the region [3] - Hubei has implemented a comprehensive service system for companies to enter the multi-level capital market, aiming to enhance the quality of enterprises [4] Group 3 - Hubei's capital market reforms have led to 20 new listings and approvals annually from 2021 to 2023, with the province ranking 6th nationally for new listings in 2024 [2] - The province aims to achieve five major goals by 2030, including increasing the total number of listed companies and ensuring coverage across all regions [4]

Group 1 - The "2025 Wuhan Investment Promotion Conference" signed 148 key projects with a total investment of 98.49 billion yuan, covering various industries such as artificial intelligence, new generation information technology, automotive manufacturing and services, new energy, new materials, biomedicine, high-end equipment manufacturing, and cultural tourism [1] - Wuhan's GDP is projected to reach 2.1 trillion yuan in 2024, reflecting a year-on-year growth of 5.2%, indicating a trend of high-quality development [1] - Garrett's global CFO announced the establishment of a second global innovation center in Wuhan, which will enhance its global R&D capabilities in zero-emission technology [1][2] Group 2 - The new innovation center will focus on creating an open innovation platform, attracting top engineering talent globally, and collaborating with academic institutions and industry partners to drive technological advancements [2] - CloudWalk Technology, a listed company on the Sci-Tech Innovation Board, announced the establishment of an intelligent computing center in Wuhan, in collaboration with Huawei, to develop a secure AI model training and deployment center [2] - Pharmaceutical company Fukan Pharmaceutical plans to invest over 2 billion yuan in Wuhan to establish production lines for innovative cancer drugs, collaborating with local hospitals and universities [2] Group 3 - Wuhan is experiencing unprecedented development opportunities due to the acceleration of a new round of technological revolution and industrial transformation, promoting the integration of technological and industrial innovation [3] - The city aims to create a first-class business environment and provide excellent services to ensure that global enterprises can invest, develop, and live comfortably in Wuhan [3]

证券代码：600998 证券简称：九州通 公告编号：临 2025-052 九州通医药集团股份有限公司 关于地塞米松磷酸钠注射液获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2025 年 6 月 20 日，九州通医药集团股份有限公司（以下简称"公司"或"九 州通"）子公司北京京丰制药集团有限公司（以下简称"京丰制药"）的下属公 司汇禹远和（海南）药业有限公司收到国家药品监督管理局核准签发的地塞米松 磷酸钠注射液《药品注册证书》。现将相关情况公告如下： 一、药品注册证书主要信息 药品名称：地塞米松磷酸钠注射液 剂型：注射剂 申请事项：药品注册（境内生产） 药品生产企业：津药和平（天津）制药有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品其他相关情况 规格：1ml:10.93mg 注册分类：化学药品 3 类 证书编号：2025S01817 药品批准文号：国药准字 H20254556 药品批准文号有效期：至 2030 ...

证券代码：600998 证券简称：九州通 公告编号：临 2025-051 九州通医药集团股份有限公司 关于股东提前解除股份质押及质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●公司股东中山广银办理完成51,729,000股的股份提前解除质押手续，公司股东上海 弘康办理完成58,000,000股的股份解除质押手续，本次解除质押股份占其所持股份的比 例分别为15.43%和5.33%，占公司总股本的比例分别为1.03%和1.15%。另外，上海弘康 办理完成64,110,000股的股份质押手续，本次质押股份占其所持股份的比例为5.89%，占 公司总股本的比例为1.27%。 ●公司股东中山广银和上海弘康分别持有公司股份335,357,275股和1,088,326,782股， 占公司总股本的比例分别为6.65%和21.58%。本次股份提前解除质押及质押办理完成后， 中山广银和上海弘康分别累计质押公司股份188,696,820股和539,571,892股，占其所持股 份的比例分别为56.27%和49.58%，占 ...

Group 1 - The core index of the China Securities Index for Food and Major Consumer Goods Retail has shown a decline of 2.40% over the past month, 6.58% over the past three months, and 6.48% year-to-date [1] - The index is composed of listed companies in the food and drug retail sector, reflecting the overall performance of these companies, with a base date of December 31, 2004, set at 1000.0 points [1] - The top ten weighted companies in the index include Yonghui Supermarket (6.61%), Digital China (6.21%), Wancheng Group (4.68%), Shanghai Pharmaceuticals (4.41%), Yifeng Pharmacy (4.32%), Jiuzhoutong (3.86%), Kidswant (3.41%), Sinopharm (3.25%), Wangfujing (3.17%), and TianKang (3.09%) [1] Group 2 - The market segments represented in the index include 43.94% in pharmaceutical commerce, 21.32% in supermarkets and convenience stores, 20.29% in specialty retail, and 14.46% in department stores [2] - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December each year [2] - In special circumstances, the index may undergo temporary adjustments, such as when a sample company is delisted or undergoes mergers, acquisitions, or splits [2]

Core Viewpoint - The article outlines the management measures for the employee stock ownership plan (ESOP) of Jiuzhoutong Pharmaceutical Group Co., Ltd. for the period 2023-2026, emphasizing compliance, voluntary participation, and risk-bearing principles. Group 1: General Principles - The ESOP will be implemented in strict accordance with relevant laws and regulations, ensuring accurate and timely information disclosure [1][2] - Participation in the ESOP is voluntary, with no forced allocation or distribution to employees [2] Group 2: Plan Implementation Procedures - The company will solicit employee opinions through representative meetings before implementing the ESOP [3] - The board of directors must approve the ESOP draft and ensure that related directors abstain from voting [3][4] - A legal opinion will be obtained before the shareholders' meeting to review the ESOP [4] - The shareholders' meeting will vote on the ESOP using a combination of on-site and online voting methods [4] Group 3: Funding and Stock Sources - The total amount of funds to be raised for the ESOP is approximately 461.69 million yuan, with each share priced at 1 yuan [5] - The ESOP will acquire stocks from the company's repurchase account and through market purchases [5] - The total scale of the ESOP is planned to be around 48.60 million shares, accounting for approximately 2.59% of the company's total share capital [5] Group 4: Lock-up Period and Performance Assessment - The lock-up period for the ESOP shares is set at 12 months from the distribution date of each batch [6][7] - Performance assessments will determine the returns for participants based on individual performance ratings [7] Group 5: Management Structure - The ESOP will be managed by a management committee elected by the participants, which will oversee daily operations and asset management [8][9] - The management committee is responsible for making decisions regarding the sale and distribution of the ESOP's assets [9] Group 6: Rights and Obligations of Participants - Participants have the right to request cash distributions or stock transfers after the lock-up period [14] - Participants are obligated to comply with the management committee's decisions regarding the ESOP [14][15]

第二条 九州通医药集团股份有限公司（以下简称"公司"）系依照《公司 法》和其他有关规定成立的股份有限公司。 第一条 为维护公司、股东、职工和债权人的合法权益，规范公司的组织和 行为，根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共 和国证券法》（以下简称《证券法》）和其他有关规定，制定本章程。 公司经湖北省商务厅（鄂商资【2008】133 号文）批准，在九州通集团有限 责任公司的基础上以整体变更方式发起设立。公司在湖北省市场监督管理局注册 登记，取得营业执照，统一社会信用代码为 9142000071451795XA。 第三条 公司于【2010 年 10 月 14 日】经中国证券监督管理委员会（以下简 称"中国证监会"）核准，首次向社会公众发行人民币普通股【150,000,000】股， 于【2010 年 11 月 2 日】在【上海证券交易所】上市。 公司于【2024 年 7 月 5 日】经中国证监会核准，公司向特定对象发行优先 九州通医药集团股份有限公司 章程 （2025 年 6 月修订） 目 录 第一章 总则 第二章 经营宗旨和范围 第三章 股份 第一节 股份发行 第二节 股份增减和回购 第三 ...

| 北京海润天睿律师事务所 | | --- | | 关于九州通医药集团股份有限公司 | | 修订 2023-2025 年员工持股计划（草案）及第三批分 | | 配的 | | 法律意见书 | | 中国·北京 | | 朝阳区建外大街甲 14 号广播大厦 17 层 邮政编码：100022 | | 电话：(010)65219696 传真:(010)88381869 | | 二〇二五年六月 | | 释义 | | 在本法律意见书中，除非文义另有所指，下列词语具有下述含义： | | 九州通、公司 指 九州通医药集团股份有限公司 | | 《九州通医药集团股份有限公司 2023-2025 年员工持股 | | 《员工持股计划（草案）》 指 | | 计划（草案）》 | | 《员工持股计划（草案修 《九州通医药集团股份有限公司 2023-2026 年员工持股 | | 指 | | 订稿）》 计划（草案）（修订稿）》 | | 2023-2025 九州通医药集团股份有限公司 年员工持股计 | | 本次员工持股计划 指 划（本次名称拟修订为九州通医药集团股份有限公司 | | 九州通医药集团股份有限公司拟修订 2023-2025 年员工 | ...

Core Viewpoint - The company has revised its employee stock ownership plan for 2023-2025, extending it to 2023-2026 and adjusting the distribution batches and proportions to enhance implementation and compliance with regulatory guidelines [1][4][5] Summary by Sections Employee Stock Ownership Plan Overview - The company established the employee stock ownership plan in meetings held on April 26, 2023, and May 19, 2023, with the first two batches already implemented in 2023 and 2024 [1][2] Revision Details - The plan's distribution has been adjusted from three batches (2023-2025) to four batches (2023-2026), with the distribution proportions revised accordingly [2][3] - The first batch in 2023 allocated up to 17.5 million shares at a subscription price of 9.50 CNY per share, while the second batch in 2024 will allocate up to 30 million shares at a price of 5.00 CNY per share [2] Procedural Changes - The approval process for the employee stock ownership plan has been updated to align with new regulatory requirements, changing the announcement procedures and terminology from "shareholders' meeting" to "shareholders' assembly" [3][4] Impact of Revisions - The revisions are expected to facilitate the ongoing implementation of the employee stock ownership plan and comply with relevant laws and regulations, ensuring no harm to the interests of the company and its shareholders [4][5] Legal Opinions - Legal counsel has confirmed that the revisions and the third batch distribution have received necessary approvals and comply with applicable laws and regulations [5]

九州通医药集团股份有限公司 关于增加经营范围暨修订《公司章程》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 届董事会第十五次会议，审议通过了《关于公司增加经营范围暨修订 <公司章程> 的 议案》；因公司业务经营范围拓展的需要，依照企业经营范围登记管理规范性要求， 公司拟增加"装卸搬运、仓储服务、物流辅助服务、餐饮服务、教育培训服务、会 务服务、会议服务、企业管理服务、法律咨询、文化创意服务、健康管理服务费、 市场推广宣传、营销策划服务、企业运营管理服务、电子商务代运营"的经营范围。 同时，根据湖北省市场监督管理局的相关要求，结合公司实际情况，修订《公司章 程》相关条款，主要修订情况如下： 原条款 修订后条款 证券代码：600998 证券简称：九州通 公告编号：临 2025-049 第十五条 第十五条 经公司登记机关核准，公司经营范围是： 经公司登记机关核准，公司经营 许可项目：药品批发；危险化学品经营......一 范围是： 般项目：第一类医疗器械销售......地产中草药 许可项目：药品批发；危险化学 （不含中药饮 ...